69 results
6-K
EX-99.1
PRTG
Portage Biotech Inc
28 Feb 24
Company focused on adenosine platform clinical development
6:42pm
include research and development (“R&D”) costs and general and administrative (“G&A”) expenses, were $4.0 million in the Fiscal 2024 Quarter, compared … to $4.8 million in the Fiscal 2023 Quarter, a decrease of $0.8 million, which is discussed more fully below.
R&D costs increased slightly
424B3
PRTG
Portage Biotech Inc
28 Feb 24
Prospectus supplement
5:19pm
period associated with the Committed Purchase (as defined below).
Operating expenses, which include R&D and general and administrative (“G&A”) expenses … ended December 31,
In 000’$
Research and development
General and administrative expenses
Total operating expenses
Research and Development Costs
R&D costs
6-K
EX-99.2
PRTG
Portage Biotech Inc
28 Feb 24
Current report (foreign)
5:17pm
, which include R&D and general and administrative (“G&A”) expenses, were $4.0 million in the Fiscal 2024 Quarter, compared to $4.8 million in the Fiscal …
Total operating expenses
Research and Development Costs
R&D costs are comprised of the following:
Three months ended December 31,
In 000’$
Research
424B3
PRTG
Portage Biotech Inc
28 Nov 23
Prospectus supplement
4:03pm
:
Operating expenses, which include R&D and general and administrative (“G&A”) expenses, were $5.9 million in the Fiscal 2024 Quarter, compared to $3.6 … expenses
Research and Development Costs
R&D costs are comprised of the following:
Three months ended September 30,
In 000’$
Research and development
6-K
EX-99.1
PRTG
Portage Biotech Inc
28 Nov 23
PORT 2 and 6 Presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting
4:02pm
million, which is discussed more fully below.
R&D costs increased by approximately $2.7 million to approximately $4.2 million, or approximately 180 … ). These increases in R&D costs reflect the clinical activity and manufacturing-related costs related to developing the Company’s adenosine and iNKT
6-K
EX-99.2
uozly40mwk47
28 Nov 23
Current report (foreign)
4:01pm
424B5
ub5ddv9 oop
2 Oct 23
Prospectus supplement for primary offering
6:01pm
6-K
EX-99.1
xby8 w5mbe7
30 Aug 23
Current report (foreign)
8:00am
6-K
EX-99.2
7hylq7x 20
29 Aug 23
Current report (foreign)
4:01pm
6-K
EX-99.1
t1zh28kk
31 Jul 23
Current report (foreign)
6:10pm
6-K
EX-99.2
jqeww0r20vpn6t4eoy4y
29 Nov 22
Current report (foreign)
4:58pm
6-K
EX-99.2
r3f1lwzfd
29 Aug 22
Current report (foreign)
4:00pm
6-K
EX-99.1
mty0ehlz51zzxgmubgj
1 Aug 22
Current report (foreign)
4:48pm
6-K
EX-99.2
jnj6i6b
25 Feb 22
Current report (foreign)
5:29pm
6-K
EX-99.1
6mv1n8s
25 Feb 22
Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year
12:00am
6-K
EX-99.2
a0czlrkj64t3mwytgy
23 Nov 21
Current report (foreign)
4:30pm
6-K
EX-99.1
530ayfwj
23 Nov 21
Portage Biotech Announces Financial Results and Provides Business Update for Second Quarter of 2022 Fiscal Year
8:00am
6-K
EX-99.2
p09okozm2dc7 uuza2vq
30 Aug 21
Current report (foreign)
5:21pm